# China Biotech
Latest news and articles about China Biotech
Total: 5 articles found
From Gold Mine to Glut: The Darkest Hour for China’s HPV Vaccine Giants
China's leading HPV vaccine manufacturers, Wantai and Zhifei, have reported record financial losses as the market shifts from scarcity to a massive oversupply. A combination of high vaccination rates among wealthy demographics and aggressive government price-cutting has collapsed profit margins, forcing a difficult strategic pivot.
The New Vanguard: China’s Biotechs Shift from Mimicry to Mastery at ASCO 2026
China has achieved a record-breaking presence at the 2026 ASCO conference, securing nearly 20% of the world's Late-Breaking Abstracts. This surge reflects a decade-long transition from generic drug manufacturing to leading-edge oncology innovation in fields like ADCs and bispecific antibodies.
China’s Nuclear Medicine Leap: Beijing Approves World-First Domestic Radiopharmaceutical
China has approved its first self-developed, world-first radiopharmaceutical, marking a transition from drug imitation to global leadership. This breakthrough in nuclear medicine underscores Beijing's successful integration of biotechnology and nuclear infrastructure.
China’s Oncology Frontier: Bioken’s Breakthrough Signals New Global Standard in Lung Cancer Treatment
Chinese biotech firm Bioken has reported record-breaking Phase II clinical results for its bispecific ADC lung cancer treatment, achieving a 100% tumor shrinkage rate in target lesions. Backed by a historic $8.4 billion deal with Bristol Myers Squibb, the company’s success highlights China’s rapid ascent from a generic drug producer to a leader in original pharmaceutical innovation.
A Veteran’s Departure: The Executive Exit Signaling a Crisis in China’s Vaccine Market
The resignation of Wantai Biological’s 20-year veteran board secretary, Yu Tao, underscores a deep crisis in China's vaccine sector. As domestic price wars slash HPV vaccine prices by 90%, the former industry leader is facing massive losses and a desperate pivot toward international markets.